超越前列腺影像报告和数据系统:联合磁共振前列腺影像报告和数据系统与前列腺特异性膜抗原-正电子发射断层扫描/计算机断层扫描PRIMARY评分构建复合(P)评分以更准确诊断临床显著前列腺癌
本研究在疑似前列腺癌、未活检、近期接受MRI和68Ga-PSMA-11 PET/CT并随后行经会阴活检的男性中,开发并外部验证了联合PI-RADS与PRIMARY评分的5分复合(P)评分。验证样本中,P评分1至5分对应的临床显著前列腺癌检出率分别为0%、20%、52%、96%和100%,曲线下面积为0.93,高于PI-RADS的0.89和PRIMARY评分的0.84。P评分计算简便,在临床显著前列腺癌诊断准确性上优于PI-RADS和PRIMARY评分。
要点
- 复合(P)评分在验证样本中临床显著前列腺癌检出率随评分1至5分递增为0%、20%、52%、96%、100%。
- P评分曲线下面积0.93,高于PI-RADS的0.89(P=0.039)和PRIMARY评分的0.84(P<0.001)。
- 以1/2分为阴性、3/4/5分为阳性,P评分对ISUP≥3癌的敏感性为99%。
核心结论
- P评分计算简便,在临床显著前列腺癌诊断准确性上优于PI-RADS和PRIMARY评分,当因诊断目的行PSMA-PET时应考虑使用。
研究设计与样本
- 开发样本为前瞻性试验中疑似前列腺癌、无既往活检、近期接受MRI和68Ga-PSMA-11 PET/CT并随后行经会阴活检的男性291例,其中56%为临床显著前列腺癌。
- 验证样本为多中心回顾性数据库中同类男性227例,其中67%为临床显著前列腺癌。
- 主要结局为临床显著前列腺癌(ISUP≥2)检出,次要结局为ISUP≥3癌检出;通过曲线下面积、敏感性、特异性和决策曲线分析评估评分表现。
主要发现
- 验证数据集中,P评分1至5分对应的临床显著前列腺癌检出率分别为0%、20%、52%、96%和100%。
- P评分曲线下面积为0.93(95%CI:0.90-0.96),高于PI-RADS的0.89(95%CI:0.85-0.93,P=0.039)和单用PRIMARY评分的0.84(95%CI:0.79-0.89,P<0.001)。
- 以1/2分为阴性、3/4/5分为阳性拆分时,P评分敏感性为94%(95%CI:89-97),PI-RADS为89%(95%CI:83-93),PRIMARY评分为86%(95%CI:79-91)。
- 对ISUP≥3癌,P评分敏感性为99%(95%CI:95-100),PI-RADS为94%(95%CI:88-98),PRIMARY评分为92%(95%CI:85-97)。
- 最大标准化摄取值>12(P评分5分)的病例全部为ISUP≥2,其中93%为ISUP≥3。
关键数值与推荐
- P评分为5分复合评分,联合单独阅读的PI-RADS和PRIMARY评分计算。
- P评分1至5分对应临床显著前列腺癌检出率0%、20%、52%、96%、100%。
- P评分曲线下面积0.93(95%CI:0.90-0.96),PI-RADS 0.89(95%CI:0.85-0.93,P=0.039),PRIMARY评分0.84(95%CI:0.79-0.89,P<0.001)。
- P评分敏感性94%(95%CI:89-97) vs PI-RADS 89%(95%CI:83-93) vs PRIMARY评分86%(95%CI:79-91)。
- 对ISUP≥3癌,P评分敏感性99%(95%CI:95-100) vs PI-RADS 94%(95%CI:88-98) vs PRIMARY评分92%(95%CI:85-97)。
临床怎么用
- 作者认为,当因诊断目的行PSMA-PET时,应考虑使用P评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Prostate Imaging Reporting and Data System (PI-RADS) score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY score (prostate-specific membrane antigen [PSMA]-positron emission tomography [PET]/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (International Society of Urological Pathology [ISUP] ≥2) incorporating separately read PI-RADS and PRIMARY scores, with external validation. MATERIALS AND METHODS: Two datasets of men with suspected PCa, no prior biopsy, recent MRI and 68Ga-PSMA-11-PET/CT, and subsequent transperineal biopsy were evaluated. These included the development sample (n = 291, 56% csPCa) a prospective trial and the validation sample (n = 227, 67% csPCa) a multicenter retrospective database. Primary outcome was detection of csPCa (ISUP ≥2), with ISUP ≥ 3 cancer detection a secondary outcome. Score performance was evaluated by area under the curve, sensitivity, specificity, and decision curve analysis. RESULTS: The 5-point combined (P) score was developed in a prospective dataset. In the validation dataset, csPCa was identified in 0%, 20%, 52%, 96%, and 100% for P score 1 to 5. The area under the curve was 0.93 (95% CI: 0.90-0.96), higher than PI-RADS 0.89 (95% CI: 0.85-0.93, P = .039) and PRIMARY score alone 0.84 (95% CI: 0.79-0.89, P < .001). Splitting scores at 1/2 (negative) vs 3/4/5 (positive), P score sensitivity was 94% (95% CI: 89-97) compared to PI-RADS 89% (95% CI: 83-93) and PRIMARY score 86% (95% CI: 79-91). For ISUP ≥ 3, P score sensitivity was 99% (95% CI: 95-100) vs 94% (95% CI: 88-98) and 92% (95% CI: 85-97) for PI-RADS and PRIMARY scores respectively. A maximum standardized uptake value > 12 (P score 5) was ISUP ≥ 2 in all cases with 93% ISUP ≥ 3. CONCLUSIONS: The P score is easily calculated and improves accuracy for csPCa over both PI-RADS and PRIMARY scores. It should be considered when PSMA-PET is undertaken for diagnosis.
引用
- Emmett L, Papa N, Hope TA, et al. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024. PMID: 38758680. doi:10.1097/JU.0000000000004010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。